IT in Healthcare Industry and market research

The introduction of a one size fits all treatment for severe diseases like Cancer has been an extended time in coming. Recently, market research projects are administered that show certain sorts of the disease may take several forms, each mutually distinct and potentially requiring different treatment methods. It is here where Companion Diagnostics can help. Using companion diagnostics allows companies to hone in on more external factors like genetics or maybe social and environmental elements to develop and tailor treatments for the requirements of a targeted group of people. It's hoped this bespoke approach to treatment will, in time, change the way drugs are developed and prescribed, saving time, money, and, more importantly, lives.

 

An integral part of treatment and market research

 

Although considerably in its infancy, there are promising signs that Companion Diagnostics can play an integral part in the way forward for the treatment of illnesses and, therefore, the healthcare industry as an entire. The tide is changing, and within the previous couple of years, many of the world's leading pharmaceutical companies have adapted their procedures to usher in a component of companion diagnostics. Instead of the off the shelf approach, which has been ubiquitous so far, customers are now starting to be targeted specifically with products and dosages which are tailored to them supported genetic and behavioral characteristics.

 

This is in stark contrast to the event of medicine as little as five years ago, where products were introduced to plug with none consideration on who they might be employed by, and whether or not they would be potentially less useful for particular groups. Now many pharmaceutical giants are beginning to work collaboratively, pooling their resources to supply drugs that are effective within the treatment of predetermined target groups. It's anticipated that this 'fine-tuning' of drug production won't only benefit patients within the first instance. If the companion diagnostics process is adopted at the conception stage of a replacement product, then tons of data can be gathered throughout the event and trial stages of the merchandise.

 

This can be hugely beneficial - with the supporting data already in place from such processes, the prospects of a drug being approved for the market are vastly improved. This will not only economize - it also can hamper the timeframe for getting treatments to the broader market - potentially saving many lives and livelihoods. However, as Companion Diagnostics is in its early stages for several, pharmaceutical companies need to hunt collaboration with a firm with experience. Inexperience can cause uncertainty, which successively may result in costly mistakes when making those critical decisions.

 

The Growth of Diagnostics in the Healthcare IT Industry

 

IT is increasingly being embraced by healthcare organizations. While for a few organizations, the motivation for IT implementation is propelled by intention to automate and modernize their functioning, many others do it to follow the fad. However, the trend is new and nascent, as compared to other countries. There's a transparent crunch of adequately qualified and relevantly experienced IT workforce during this domain, then far, it's not been smooth sailing for many organizations. Among all this, people that face most of the brunt are those that are managing IT in healthcare organizations. In reality, the company power center remains with CEOs/COOs/CFOs, mainly when it involves actual decision-making love its budgeting. Reasons would be anything ranging from lack of funds, weak business case, internal resistance, or many a time, just ignorance.

 

Quite evidently, there's a true got to rationalize the facility play inside corporate boardrooms!

 

Healthcare is possibly among the foremost data-critical, information-intensive, and knowledge-driven service sectors. Yet, for long, the industry (particularly within the Indian context) has been one of the slowest adopters of IT. Currently, the IT penetration in the Indian healthcare industry is much too small compared to global standards and consistent with industry analysts; it'll be a short time before the health IT market blossoms.

 

Interestingly, the rationale for such slow market growth for health IT and hospital automation solutions and services isn't solely thanks to the lack of funds of healthcare providers. Significant investment is already happening for healthcare infrastructure development/expansion and medical equipment, but not comparably, so for health IT. While the general healthcare market in India is predicted to succeed in nearly USD 70 billion by 2012, the potential for the medical equipment market over an equivalent period is pegged at USD 18 billion, while that of the health IT market at USD 3 billion.